Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG09222 for prevention of migraine in patients with prior unsuccessful preventive treatments
2020-005924-12Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Aug 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing Lu AG09222 with Placebo (2 arms). Primary endpoint: Change in Monthly Migraine Days at Month 1. Started Aug 2021; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on 2020-005924-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005924-12.